Combined therapy of low dose cisplatin and protracted infusion of 5-fluorouracil with radiotherapy in inoperable esophageal cancer patients.
スポンサーリンク
概要
- 論文の詳細を見る
[Purpose] To determine the efficacy and toxicity of combined therapy of low-dose cisplatin (CDDP) and protracted infusion 5-fluorouracil (5-FU) with radiotherapy (RT) in patients strictly diagnosed as having stage N esophageal cancer.[Patients and Methods] Patients, who were diagnosed as having either T 4, N 4 or M 1 by TNM classification and with measurable lesions, were eligible for this study. Low-dose CDDP was administered intravenously at a dose of 7 mg/m<SUP>2</SUP>/day over 1 hour, followed by RT at a dose of 2 Gray (Gy)/fraction/day on days 1-5, 8-12, 15-19, 22-26. Protracted intravenous infusion of 5-FU was performed at a dose of 200 mg/m<SUP>2</SUP>/day for 28 days. After one week of rest, RT boost was given to the locoregional area 5 days a week over 2 weeks. The cumulative dose of radiation was 60 Gy (LDFPX regimen).[Results] Fourteen patients were enrolled in this study, and all of them were assessable for response and toxicity. There were one CR (complete response) and 8 PR (partial response) out of 14 patients, with a resulting the response rate of 64%. The median time to progression and the median duration of response were 10 and 8 months, respectively. The median overall survival was 7. 5 months, and the survival rate at one year was 26. 8%. The major side effects were leukopenia and neutropenia.[Conclusions] LDFPX therapy seems to be as active as other therapies previously reported for advanced esophageal cancer. The adverse events were found to be less toxic both hematologically and nonhematologically than other therapies. These results suggest that LDFPX therapy is useful, especially for patients with poor performance status.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.